Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TheraCIM hR3 nimotuzumab: Preliminary Phase I/II data

Preliminary data from the first 2 cohorts in a Canadian Phase I/II trial showed that all 13 patients receiving nimotuzumab

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE